Abstract
Anticoagulants are used to prevent the formation and extension of blood clots in various disorders as prophylactic agents for thrombo-embolic disorders. Designing of specific inhibitors against molecular targets that play a pivotal role in the coagulation cascade is indispensable. Clotting Factor Xa is one such attractive target for the design of new oral anticoagulants because of the unique role factor Xa plays in the coagulation cascade as a connection between the extrinsic and intrinsic pathways. Application of computational techniques in drug discovery process helps in identifying parameters which can lead to achieve better pharmacological profile. The docking interactions and QSAR studies performed on series of 4-methy-3-(6-[phenyl methylene] amino} pyridine-3-yl)-2H chromen-2-one derivatives provide significant insights for designing of better ligands as anticoagulants.
Keywords: 3D QSAR, Activated Partial Thromboplastin Time, Chromen-2-one, Molecular Docking, Prothrombin time, Anticoagulants, Pharmaceutical Chemistry, Clotting Factor, pyridine, thromboplastin
Medicinal Chemistry
Title:Identification of Structural Features for 4-Methyl-3-(6-[Phenyl Methylene] Amino} Pyridine-3-yl)-2h Chromen-2-One Derivatives as Clotting Factor XA Inhibitors
Volume: 8 Issue: 2
Author(s): Kundan B. Ingale, Manish S. Bhatia
Affiliation:
Keywords: 3D QSAR, Activated Partial Thromboplastin Time, Chromen-2-one, Molecular Docking, Prothrombin time, Anticoagulants, Pharmaceutical Chemistry, Clotting Factor, pyridine, thromboplastin
Abstract: Anticoagulants are used to prevent the formation and extension of blood clots in various disorders as prophylactic agents for thrombo-embolic disorders. Designing of specific inhibitors against molecular targets that play a pivotal role in the coagulation cascade is indispensable. Clotting Factor Xa is one such attractive target for the design of new oral anticoagulants because of the unique role factor Xa plays in the coagulation cascade as a connection between the extrinsic and intrinsic pathways. Application of computational techniques in drug discovery process helps in identifying parameters which can lead to achieve better pharmacological profile. The docking interactions and QSAR studies performed on series of 4-methy-3-(6-[phenyl methylene] amino} pyridine-3-yl)-2H chromen-2-one derivatives provide significant insights for designing of better ligands as anticoagulants.
Export Options
About this article
Cite this article as:
Kundan B. Ingale, Manish S. Bhatia , Identification of Structural Features for 4-Methyl-3-(6-[Phenyl Methylene] Amino} Pyridine-3-yl)-2h Chromen-2-One Derivatives as Clotting Factor XA Inhibitors , Medicinal Chemistry 2012; 8 (2) . https://dx.doi.org/10.2174/157340612800493728
DOI https://dx.doi.org/10.2174/157340612800493728 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Antiplatelet Agents in the Management of Patients Receiving Intracardiac Closure Devices
Current Pharmaceutical Design Effects of Filtration on the Presence of Particulate and Oxycodone Content of Injections Prepared from Crushed OxyContin® Tablets
Current Drug Safety Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond
Current Pharmaceutical Design Thrombophilia and Female Sex Hormones
Current Women`s Health Reviews Retroviral Vector-mediated Gene Therapy for Metabolic Diseases: An Update
Current Pharmaceutical Design Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Safety and Efficacy of Bridging with Low Molecular Weight Heparins: A Systematic Review and Partial Meta-Analysis
Current Pharmaceutical Design Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Current Guidelines and Strategies in Management of Renal Vein Thrombosis
Current Pediatric Reviews Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design